RG-101 is a novel anti-miR-122 oligonucleotide therapeutic that is effectively targeted to hepatocytes for the treatment of HCV through conjugation to GalNAc, a carbohydrate-based chemistry approach for asialoglycoprotein
receptor-mediated delivery of oligonucleotides to hepatocyte cells of the liver.
This study evaluated the usefulness of asialoglycoprotein
receptor scintigraphy with [sup.
Topology of asialoglycoprotein
receptor in rat liver subcellular fractions: a ferritin immunoelectron microscopic study.
receptor facilitates hemolysis in patients with alcoholic liver cirrhosis.
On the sinusoidal surface of the hepatocytes, asialoglycoprotein
receptors are expressed abundantly which removes the asialo (galactose-terminal) glycoproteins from the sinusoidal circulation by internalizing the bound protein via endocytosis.
Using the hepatocyte-specific asialoglycoprotein
receptor and the substance that specifically binds to it (i.
12] analogs and transporting them to the liver via an asialoglycoprotein
receptor for secretion into bile.
Earlier research hinted that another cell-surface molecule, the asialoglycoprotein
receptor, is an entry point for Marburg virus.
GalNAc-siRNA conjugates are a proprietary Alnylam delivery platform and are designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein
A 3D model for the human hepatic asialoglycoprotein
GalNAc-siRNAs are designed to achieve targeted delivery of RNAi therapeutics to hepatocyte cells of the liver through uptake by the asialoglycoprotein
For example, competition for clearance by the asialoglycoprotein
receptor of the liver between asialylated intestinal ALP and asialoglycoproteins
can lead to increased serum concentrations of intestinal ALP (5).